Form DEF 14A Response Oncology Inc

DEF 14A - Other definitive proxy statements

Published: 1999-04-30 00:00:00
Submitted: 1999-04-30
Period Ending In: 1999-06-10
FEXt:txt
0000950144-99-005191.txt Complete submission text file
-----BEGIN PRIVACY-ENHANCED MESSAGE-----
Proc-Type: 2001,MIC-CLEAR
Originator-Name: webmaster@www.sec.gov
Originator-Key-Asymmetric:
 MFgwCgYEVQgBAQICAf8DSgAwRwJAW2sNKK9AVtBzYZmr6aGjlWyK3XmZv3dTINen
 TWSM7vrzLADbmYQaionwg5sDW3P6oaM5D3tdezXMm7z1T+B+twIDAQAB
MIC-Info: RSA-MD5,RSA,
 SOCuvxf7ZsnnTk2zWxJSW+R/akfIuwKnYxF0p/YQYms9615aHCN4xoHqP/cTZXNW
 XdAQcjXgESjuIJLOvJB0/A==

<SEC-DOCUMENT>0000950144-99-005191.txt : 19990503
<SEC-HEADER>0000950144-99-005191.hdr.sgml : 19990503
ACCESSION NUMBER:		0000950144-99-005191
CONFORMED SUBMISSION TYPE:	DEF 14A
PUBLIC DOCUMENT COUNT:		1
CONFORMED PERIOD OF REPORT:	19990610
FILED AS OF DATE:		19990430

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			RESPONSE ONCOLOGY INC
		CENTRAL INDEX KEY:			0000763098
		STANDARD INDUSTRIAL CLASSIFICATION:	SERVICES-SPECIALTY OUTPATIENT FACILITIES, NEC [8093]
		IRS NUMBER:				621212264
		STATE OF INCORPORATION:			TN
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		DEF 14A
		SEC ACT:		
		SEC FILE NUMBER:	001-09922
		FILM NUMBER:		99607987

	BUSINESS ADDRESS:	
		STREET 1:		1775 MORIAH WOODS BLVD
		CITY:			MEMPHIS
		STATE:			TN
		ZIP:			38117
		BUSINESS PHONE:		9017617000

	MAIL ADDRESS:	
		STREET 1:		1775 MORIAH WOODS BLVD
		CITY:			MEMPHIS
		STATE:			TN
		ZIP:			38117

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	RESPONSE TECHNOLOGIES INC
		DATE OF NAME CHANGE:	19920703

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	BIOTHERAPEUTICS INC
		DATE OF NAME CHANGE:	19891221
</SEC-HEADER>

Form DEF 14A 1 RESPONSE ONCOLOGY, INC


<PAGE>   1

                                  SCHEDULE 14A
                                 (RULE 14A-101)
 
                    INFORMATION REQUIRED IN PROXY STATEMENT
 
                            SCHEDULE 14A INFORMATION
          PROXY STATEMENT PURSUANT TO SECTION 14(a) OF THE SECURITIES
                    EXCHANGE ACT OF 1934 (AMENDMENT NO.   )
 
Filed by the Registrant [X]
 
Filed by a Party other than the Registrant [ ]
 
Check the appropriate box:
 
<TABLE>
<S>                                             <C>
[ ]  Preliminary Proxy Statement                [ ]  Confidential, for Use of the Commission
                                                     Only (as permitted by Rule 14a-6(e)(2))
[X]  Definitive Proxy Statement
[ ]  Definitive Additional Materials
[ ]  Soliciting Material Pursuant to ss 240.14a-11(c) or ss 240.14a-12
</TABLE>

                            Response Oncology, Inc.
- --------------------------------------------------------------------------------
                (Name of Registrant as Specified In Its Charter)


- --------------------------------------------------------------------------------
    (Name of Person(s) Filing Proxy Statement, if other than the Registrant)
 
Payment of Filing Fee (Check the appropriate box):
 
[X]  No fee required.
 
[ ]  Fee computed on table below per Exchange Act Rules 14a-6(i)(4) and 0-11.
 
     (1)  Title of each class of securities to which transaction applies:
 
     (2)  Aggregate number of securities to which transaction applies:
 
     (3)  Per unit price or other underlying value of transaction computed
          pursuant to Exchange Act Rule 0-11 (set forth the amount on which the
          filing fee is calculated and state how it was determined):
 
     (4)  Proposed maximum aggregate value of transaction:
 
     (5)  Total fee paid:
 
[ ]  Fee paid previously with preliminary materials:
 
[ ]  Check box if any part of the fee is offset as provided by Exchange Act Rule
     0-11(a)(2) and identify the filing for which the offsetting fee was paid
     previously. Identify the previous filing by registration statement number,
     or the Form or Schedule and the date of its filing.
 
     (1)  Amount Previously Paid:
 
     (2)  Form, Schedule or Registration Statement No.:
 
     (3)  Filing Party:
 
     (4)  Date Filed:
<PAGE>   2
                             RESPONSE ONCOLOGY, INC.

                    NOTICE OF ANNUAL MEETING OF SHAREHOLDERS
                           TO BE HELD ON JUNE 10, 1999


         NOTICE IS HEREBY GIVEN that the 1999 Annual Meeting of the Shareholders
of Response Oncology, Inc. (the "Annual Meeting") will be held at the offices of
Response Oncology, Inc. (the "Company"), 1805 Moriah Woods Blvd., Memphis,
Tennessee 38117 on Thursday, June 10, 1999, at 11:00 a.m., local time, for the
following purposes:

         1.       To elect three Class III directors to serve one year terms
                  ending in 2000, or until their successors have been duly
                  elected and qualified.

         2.       To ratify the selection of KPMG LLP as the Company's
                  independent auditors for 1999.

         Only shareholders of the Company of record as of the close of business
on April 20, 1999 will be entitled to notice of, and to vote at, the Annual
Meeting and any adjournment thereof.

         There is enclosed, as a part of this Notice, a Proxy Statement which
contains further information regarding the meeting and the above proposals.

                                         BY ORDER OF THE BOARD OF DIRECTORS




                                          Mary E. Clements
                                             Secretary
April 25, 1999








- ------------------------------------------------------------------------------

         SHAREHOLDERS WHO DO NOT EXPECT TO ATTEND THE MEETING ARE REQUESTED TO
COMPLETE, DATE, SIGN AND RETURN THE ACCOMPANYING PROXY IN THE ENCLOSED ENVELOPE.
SHAREHOLDERS WHO ATTEND THE MEETING MAY VOTE IN PERSON EVEN IF THEY HAVE ALREADY
SENT IN A PROXY.
- ------------------------------------------------------------------------------


<PAGE>   3


                             RESPONSE ONCOLOGY, INC.
                             1805 MORIAH WOODS BLVD.
                            MEMPHIS, TENNESSEE 38117

                                   ----------

                                 PROXY STATEMENT

                                   ----------



                               GENERAL INFORMATION


     THIS PROXY STATEMENT is provided in connection with the solicitation of
proxies by the Board of Directors of Response Oncology, Inc. (the "Company") for
use at the annual meeting of shareholders to be held on June 10, 1999, (the
"Annual Meeting") and any adjournment thereof. The mailing address of the
principal executive offices of the Company is 1805 Moriah Woods Blvd., Memphis,
Tennessee 38117. This Proxy Statement and the Proxy Form, Notice of Meeting and
the Company's Annual Report, all enclosed herewith, are first being mailed to
the shareholders of the Company on or about May 10, 1999.

No person is authorized to give any information or to make any representation
not contained in this Proxy Statement and, if given or made, such information or
representation should not be relied upon as having been authorized. This Proxy
Statement does not constitute the solicitation of a proxy in any jurisdiction
where, or from any person to whom it is unlawful to make such proxy
solicitation. The delivery of this Proxy Statement shall not, under any
circumstances, imply that there has not been any change in the information set
forth herein since the date of the Proxy Statement.

THE PROXY

         The solicitation of proxies is being made on behalf of the Board of
Directors of the Company primarily by the use of the mails. The cost of
preparing and mailing this Proxy Statement and accompanying material, and the
cost of any supplementary solicitation, which may be made by mail, telephone,
telegraph or personally by officers and employees of the Company (who will
receive no additional compensation for such activities), will be borne by the
Company. The shareholder giving the proxy has the power to revoke it by
delivering written notice of such revocation to the Secretary of the Company
prior to the Annual Meeting or by attending the meeting and voting in person.
Arrangements will also be made with brokerage houses and other custodians,
nominees and fiduciaries to forward solicitation materials to the beneficial
owners of shares held of record by such persons.

         Shares of the Company's common stock, $.01 par value per share ("Common
Stock") represented by properly executed proxies, unless previously revoked,
will be voted in accordance with the instructions on such proxies. If no
instruction is indicated on the proxy, the named holders of the proxies will
vote such shares of Common Stock (i) FOR the election of all Class III director
nominees named in the Proxy Statement; and (ii) FOR the ratification and
selection of KPMG LLP as the Company's independent auditors for 1999. The named
holders of proxies also will use their discretion in voting the Shares of Common
Stock in connection with any other business that properly may come before the
Annual Meeting.

VOTING RIGHTS

         Each outstanding share of Common Stock is entitled to one vote.
Cumulative voting is not permitted. Only shareholders of record at the close of
business on April 20, 1999 will be entitled to notice of, and to vote at, the
Annual Meeting and any adjournment thereof. As of the close of business on April
20, 1999, the Company had outstanding 



                                       2
<PAGE>   4

11,931,731 shares of Common Stock. Of the total number of outstanding shares of
Common Stock on April 20, 1999, the directors and executive officers of the
Company, consisting of 11 persons, owned 909,552 shares comprising 7.62% of such
total.

         No specific provision of the Tennessee Business Corporation Act, the
Company's charter or the Company's Bylaws addresses the issue of abstentions or
broker non-votes. Brokers holding shares for beneficial owners must vote those
shares according to the specific instructions they receive from the owners.
However, brokers or nominees holding shares for beneficial owners may not have
discretionary voting power and may not have received voting instructions from
the beneficial owner with respect to voting on certain proposals. In such cases,
absent specific voting instructions from the beneficial owner, the broker may
not vote on these proposals. This results in what is known as a "broker
non-vote". A "broker non-vote" will not be counted as votes cast but will be
counted for the purposes of determining the existence of the quorum. Because the
election of directors and ratification of the selection of independent auditors
or routine matters for which specific instructions from beneficial owners will
not be required, the Company does not anticipate that any "broker non-votes"
will arise in the context of the election of directors or the ratification of
the selection of independent auditors. Votes "withheld" from a director-nominee
or from the ratification of the selection of independent auditors have the
effect of a negative vote because a plurality of the votes cast at the Annual
Meeting is required for the election of each director and the ratification of
the selection of independent auditors.


                                       3
<PAGE>   5



                                  REQUIRED VOTE

         Approval of each matter submitted to the shareholders of the Company
for a vote at the Annual Meeting will require the affirmative vote of a majority
of the shares of Common Stock voting at the Annual Meeting in person or by
proxy.

                     OWNERSHIP OF THE COMPANY'S COMMON STOCK

SECURITY OWNERSHIP OF CERTAIN BENEFICIAL OWNERS.

         The following table sets forth information as of April 20, 1999,
regarding each person known to the Company to be the beneficial owner of more
than five percent of its Common Stock:


<TABLE>
<CAPTION>

                                                     AMOUNT AND NATURE OF
          NAME OF BENEFICIAL OWNER                     BENEFICIAL OWNER                  PERCENT OF CLASS (1)
          ------------------------                     ----------------                  --------------------
<S>                                                  <C>                                 <C>  
Dalton, Greiner, Hartman, Maher & Co.
1100 Fifth Avenue South, Ste. 301
Naples, Florida 34102                                      868,800                               7.28%

Dimensional Fund Advisors, Inc.
1299 Ocean Avenue, 11th Floor
Santa Monica, CA  90401                                    803,949                               6.73%

William D. Grant
One Ward Parkway, Ste. 130
Kansas City, MO  64112                                     995,577                               8.34%

Southern Fiduciary Trust
2325 Crestmoor Road, Ste. 202
Nashville, TN  37215                                       626,629                               5.25%

William H. West, M.D.
1805 Moriah Woods Blvd.
Memphis, TN 38117                                          900,129 (2)                           7.38%
</TABLE>



(1)      The percentages shown are based on 11,931,731 shares of Common Stock
         outstanding on April 20, 1999 plus, as to each individual and group
         listed, the number of shares of Common Stock deemed to be owned by such
         holder, for purposes of Rule 13d-3 under the Securities Exchange Act of
         1934, assuming conversion of the Company's Series A Preferred Stock and
         exercise of all options and warrants held by such holder, which stock,
         options and warrants may be converted or exercised within sixty (60)
         days of April 20, 1999.

(2)      Includes 259,149 shares of Common Stock which Dr. West has the right to
         acquire pursuant to the exercise of options.



                                       4
<PAGE>   6


SECURITY OWNERSHIP OF MANAGEMENT

         The following table sets forth the beneficial ownership of Common Stock
all as of April 20, 1999 by (i) each director, (ii) each director nominee, (iii)
each executive officer named in the Summary Compensation Table, and (iv) all
directors, nominees and executive officers as a group. None of the Company's
executive officers or directors is a beneficial owner of any of the Company's
Series A Preferred Stock.

<TABLE>
<CAPTION>

                                                            AMOUNT AND NATURE OF   PERCENT OF
                  NAME OF BENEFICIAL OWNER                  BENEFICIAL OWNERSHIP    CLASS (1)
                  ------------------------                  --------------------   ----------
                  <S>                                        <C>                   <C>  
                  Frank M. Bumstead                                              
                  Director                                        126,781(2)         1.06%

                  Joseph T. Clark                                                          
                  Director, President and Chief
                  Executive Officer                               388,349(3)         3.15%

                  Mary E. Clements                                                         
                  Chief Financial Officer                         130,000(4)         1.08%

                  W. Thomas Grant II                                          
                  Director                                        121,378(5)         1.02%

                  P. Anthony Jacobs                                           
                  Director                                         46,076(6)            *

                  Leonard A. Kalman, M.D.                                     
                  Director                                         43,020(7)            *

                  Lawrence N. Kugelman                                        
                  Director                                         19,000(8)            *

                  Kenneth L. Scott                                                         
                  Chief Operating Officer                         157,731(9)         1.30%

                  Carlton N. Sedberry                                                      
                  EVP Development                                 126,555(10)        1.05%

                  James R. Seward                                             
                  Director                                         39,117(10)           *
                  William H. West, M.D.
                  Chairman                                        900,129(12)        7.38%

                  ALL DIRECTORS AND OFFICERS AS A    
                  GROUP (11 PERSONS)                            2,098,136(13)       15.99%
</TABLE>


(1)      The percentages shown are based on 11,931,731 shares of Common Stock
         outstanding on April 20, 1999 plus, as to each individual and group
         listed, the number of shares of Common Stock deemed to be owned by such
         holder, for purposes of Rule


                                       5
<PAGE>   7

         13d-3 under the Securities Exchange Act of 1934, assuming conversion of
         the Company's Series A Preferred Stock and exercise of all options held
         by such holder, which stock options may be converted or exercised
         within sixty (60) days of April 20, 1999.

(2)      Includes 18,000 shares of Common Stock which Mr. Bumstead has a right
         to acquire pursuant to the exercise of options and warrants.

(3)      Includes 383,549 shares of Common Stock which Mr. Clark has the right
         to acquire pursuant to the exercise of options.

(4)      Represents shares of Common Stock which Ms. Clements has the right to
         acquire pursuant to the exercise of options.

(5)      Includes 18,000 shares of Common Stock which Mr. Grant has the right to
         acquire pursuant to the exercise of options.

(6)      Includes 18,000 shares of Common Stock which Mr. Jacobs has the right
         to acquire pursuant to the exercise of options.

(7)      Includes 43,000 shares of Common Stock which Dr. Kalman has the right
         to acquire pursuant to the exercise of options and 20 shares held by
         his wife in an IRA.

(8)      Includes 17,000 shares of Common Stock which Mr. Kugelman has the right
         to acquire pursuant to the exercise of options.

(9)      Includes 157,331 shares of Common Stock which Mr. Scott has the right
         to acquire pursuant to the exercise of options.

(10)     Represents shares of common stock which Mr. Sedberry has the right to
         acquire pursuant to the exercise of options.

(11)     Includes 18,000 shares of Common Stock which Mr. Seward has the right
         to acquire pursuant to the exercise of options.

(12)     Includes 259,149 shares of Common Stock which Dr. West has the right to
         acquire pursuant to the exercise of options.

(13)     Includes 1,188,584 shares of Common Stock as to which various officers
         and directors have rights to acquire pursuant to the exercise of
         options and conversion rights on note payments.

*        Represents less than 1% of total outstanding Common Stock


                                       6

<PAGE>   8


                                 PROPOSAL NO. 1
                              ELECTION OF DIRECTORS

COMMITTEES AND MEETINGS OF THE BOARD OF DIRECTORS

         Director Meetings. The business of the Company is under the general
management of its Board of Directors as provided by the Company's by-laws and
the laws of Tennessee, the Company's state of incorporation. The Board of
Directors regularly meets quarterly during the Company's fiscal year. There are
presently eight directors, six of whom are not executive officers or employees
of the Company ("Independent Directors"). The Board of Directors held three
meetings during fiscal 1998. No director attended fewer than 75% of the meetings
of the Board of Directors and committees during the year.

         Executive Committee. The Board of Directors has established an
Executive Committee, which currently consists of Messrs. Bumstead, Jacobs and
Seward, each of whom is an Independent Director, Mr. Clark and Dr. West. The
Executive Committee was created to have more routine, detailed meetings with
management and is empowered to act on behalf of the Board of Directors between
meetings when such action is considered necessary. The Executive Committee met
three times during fiscal 1998.

         Audit Committee. The Board of Directors has established an Audit
Committee, which currently consists of Messrs. Bumstead, Kugelman, Jacobs and
Seward (Chairman) each of whom is an Independent Director. The Audit Committee
provides assistance and advice to the board of directors on auditing and related
matters and reviews management's selection of independent auditors. The Audit
Committee met four times during fiscal 1998.

         Nominating and Compensation Committee. The Board of Directors has
established a Compensation Committee, which currently consists of Messrs.
Bumstead, Kugelman, Jacobs (Chairman) and Seward each of whom is an Independent
Director. The Compensation Committee reviews compensation, including stock
incentives, of the Company's executive officers, and makes recommendations to
the Board of Directors with respect to such compensation matters. The
Compensation Committee also administers the Company's 1990 Non-Qualified Stock
Option Plan and the 1996 Stock Incentive Plan. The Compensation Committee serves
as the Nominating Committee of the Company. The Compensation Committee met three
times during fiscal 1998.

COMPENSATION OF DIRECTORS

         Directors who are executive officers or employees of the Company do not
receive additional remuneration as directors. Independent Directors receive an
annual retainer fee of $10,000, $1,500 for each board meeting attended, and $750
for each committee meeting attended. Such compensation is payable in respect of
all duly noticed meetings and is payable whether the director attends in person
or by telephone. Such compensation may be deferred at the election of the
director and paid later in cash or in shares of Common Stock. Independent
Directors are granted options to purchase 1,000 shares of Common Stock during
each calendar quarter of service as a director of the Company. To ensure
compliance with Rule 16b-3 under the Securities Exchange Act of 1934, no options
granted to such Independent Directors may be exercised earlier than six months
from the date of the grant. All directors of the Company are eligible to receive
reimbursement of expenses, if any, incurred in attending meetings of the board
of directors and committees thereof.

NOMINEES FOR DIRECTORS

         The Company's Charter divides the board of directors into three
classes, with each having not less than one director nor more than five
directors. Class I directors are elected for terms of three years; Class II
directors for terms of two years; and Class III directors for terms of one year.
The Board of Directors has set at eight the number of directors constituting the
full Board of Directors.


                                       7
<PAGE>   9


         The following three individuals have been nominated for election to
serve as directors of the Company. Messrs. Clark, Seward and Grant are currently
directors of the Company. See "Certain Transactions with Directors" and
"Business Relationships between Company and Directors." The remaining members of
the Board of Directors listed below will continue as members thereof until their
respective terms expire as indicated below.

         Unless a shareholder specifies otherwise, it is intended that such
shareholder's shares of Common Stock will be voted FOR the election of the
nominees to serve as directors until the expiration of their respective terms
and until their successors are elected and qualified. If any nominee shall
become unavailable or unwilling to serve the Company as a director for any
reason, the persons named in the Proxy Form are expected to consult with the
management of the Company in voting the shares represented by them. The Board of
Directors has no reason to doubt the availability of any of the nominees, and
each has indicated his willingness to serve as a director of the Company if
elected.

                          DIRECTOR NOMINEES - CLASS III
                              (TERMS EXPIRING 2000)

JOSEPH T. CLARK, age 43, has been a director of the Company since 1988. Mr.
Clark has served as the Chief Executive Officer of the Company since January
1996 and as President of the Company since February 1993. Mr. Clark was formerly
the Executive Vice President and Chief Operating Officer of the Company from May
1989 to February 1993 and Secretary of the Company from September 1988 to
February 1993. Mr. Clark also served as Chief Financial Officer of the Company
from March 1988 to May 1989.

Committees: Executive

JAMES R. SEWARD, age 46, has been a director of the Company since 1990. Mr.
Seward served as the President and Chief Executive Officer of SLH Corporation
from December 1996 to August 1998 and is presently the manager of Seward and
Company, L.L.C., a consulting entity. Mr. Seward previously served as the
Executive Vice President of Seafield Capital Corporation from May 1993 to July
1997 and was the Senior Vice President of Seafield Capital Corporation from
August 1990 to May 1993. Mr. Seward also served as the Chief Financial Officer
of Seafield Capital Corporation from February 1991 to July 1997. Mr. Seward
serves as a Director of Lab One, Inc., Concorde Career Colleges and Syntroleum,
Inc. Mr. Seward is a Chartered Financial Analyst.

Committees: Compensation, Executive, and Audit (Chairman)

W. THOMAS GRANT II, age 48, has been a director of the Company since 1991. Mr.
Grant has been the Chief Executive Officer of Lab One, Inc. since July 1997. Mr.
Grant was the Chief Executive Officer of Seafield Capital Corporation and served
as the Chairman of the Board of Seafield Capital Corporation from May 1993 to
July 1997, prior to which time he served as the President. Mr. Grant serves as a
director for AMC Entertainment, Inc., Kansas City Power & Light Company,
Commerce Bancshares, Inc., Lab One, Inc. and SLH Corporation.

Committees: None

                          INCUMBENT DIRECTORS - CLASS I
                              (TERMS EXPIRING 2001)

WILLIAM H. WEST, M.D., age 51, has been a director of the Company since 1985. He
has served as Chairman of the Board of Directors of the Company since February
1993. Dr. West served as Chief Executive Officer of the Company from May 1989 to
January 1996 and Medical Director of the Company from 1985 to February 1996. Dr.
West served as President of the Company from May 1989 to February 1993.

Committees:  Executive


                                        8
<PAGE>   10


FRANK M. BUMSTEAD, age 57, has been a director of the Company since 1985. He has
served as the Vice-Chairman of the Board of the Company since February 1993. Mr.
Bumstead was the Chairman of the Board of the Company from January 1989 to
February 1993. He has been the President and Chief Executive Officer of Flood,
Bumstead, McCready and McCarthy, Inc., a financial management and business
consulting firm, since January 1990. Mr. Bumstead is also a director of First
Union National Bank of Tennessee, Syntroleum Inc., American Retirement
Corporation, TBA Entertainment, Inc and Imprint Records, Inc., serving on the
compensation committees of the latter two companies. Mr. Bumstead serves as the
Chairman of the executive committee of American Retirement Corporation

Committees: Compensation, Executive (Chairman), and Audit


LEONARD A. KALMAN, M.D., age 48, has been a director of the Company since 1996.
Dr. Kalman is a practicing medical oncologist with Oncology Hematology Group of
South Florida, P.A., where he has practiced for more than 7 years.

Committees: None


                         INCUMBENT DIRECTORS - CLASS II
                              (TERMS EXPIRING 2001)


P. ANTHONY JACOBS, age 57, has been a director of the Company since 1990. Since
September, 1997 Mr. Jacobs has served as President of CEO of Lab Holdings, Inc.
From May 1993 to September 1997 Mr. Jacobs served as President of Seafield
Capital Corporation and as Chief Operating Officer from May 1990 to September
1997. From December 1996 to August 1998, Mr. Jacobs also served as Chairman of
the Board of SLH Corporation. Mr. Jacobs is a director of Lab Holdings, Inc.,
Trenwick Group, Inc., and Syntroleum, Inc.

Committees: Compensation (Chairman), Executive, and Audit

LAWRENCE N. KUGELMAN, age 56, has been a director of the Company since August
1996. Mr. Kugelman has been a self-employed health care consultant since October
1996. From December 1995 to October 1996, he served as President and Chief
Executive Officer of Coventry Corp. From April 1995 to December 1995, Mr.
Kugelman was a self-employed health care consultant. From January 1993 to April
1995, he was Executive Vice President of American Medical International, and
prior to that he was President and Chief Executive Officer of Health Plan of
America. Mr. Kugelman is also a director of Coventry Corp.

Committees: Compensation and Audit


                                       9
<PAGE>   11


CERTAIN TRANSACTIONS WITH DIRECTORS

         In January 1996, the Company acquired from Dr. Kalman all common stock
owned by Dr. Kalman in Oncology Hematology Group of South Florida, P.A. (the
"Group") for an aggregate purchase price of approximately $1,540,000. As partial
consideration for the acquisition, the Company executed a promissory note
payable to the stockholders of the Group in the principal amount of
approximately $5,960,000, of which Dr. Kalman's beneficial interest is
approximately $745,000. The note bears interest at the rate of 9% per annum and
is payable in 59 consecutive equal amortized installments of principal and
interest. Payments on the note may be received, at the election of the Group, in
shares of Common Stock based on a conversion rate of $11.50 per share. As of the
date hereof, approximately $965,000 remains payable to the Group of which Dr.
Kalman's beneficial interest is approximately $120,000.

BUSINESS RELATIONSHIPS BETWEEN COMPANY AND DIRECTORS

         The Company and the Group, of which Dr. Kalman is a stockholder, are
parties to a management services agreement, executed in January 1996 and amended
in August 1997 in connection with the above-described physician practice
affiliation transaction, pursuant to which the Group pays the Company service
fees in exchange for the Company managing all of the non-medical aspects of the
Group's oncology practice. The agreement presently provides for the payment by
the Group of service fees equal to a percentage of the practice's net operating
income plus clinic expenses. During 1998, the Group paid the Company aggregate
service fees of approximately $8,500,000.

                             EXECUTIVE COMPENSATION

EXECUTIVE OFFICERS OF THE COMPANY

WILLIAM H. WEST, M.D., CHAIRMAN: Dr. West has served as Chairman of the Board
since February 1993 and Chief Medical Officer since October 1998. Previously, he
served as Chief Executive Officer from May 1989 to January 1996 and as Chief
Medical Officer from 1985 to February 1996. Dr. West, who is a medical
oncologist and founder of the West Clinic (a medical oncology clinic in
Memphis), has been a Director of the Company since 1985. In addition, Dr. West
has served as a Senior Researcher at the National Cancer Institute and he has
had numerous articles published in major industry publications, including THE
NEW ENGLAND JOURNAL OF MEDICINE.

JOSEPH T. CLARK, PRESIDENT AND CHIEF EXECUTIVE OFFICER: Mr. Clark has served as
Chief Executive Officer of the Company since January 1996 and President since
February 1993. From 1978 to 1982, Mr. Clark served as a hospital administrator
with Humana. From 1982 to 1988, he was with American Medical International in
various capacities, including Regional Director of Finance. Mr. Clark has been a
Director of the Company since 1988.

MARY E. CLEMENTS, CHIEF FINANCIAL OFFICER: Ms. Clements has been Chief Financial
Officer of the Company since June 1997. Before joining Response Oncology in June
1996, she served in a number of capacities at Coopers & Lybrand L.L.P.,
performing various auditing and consulting functions for several physician
practice management companies. From June 1996 to September 1996, Ms. Clements
served as Director of Development for the Company's Practice Management
Division. In September 1996, she was appointed Chief Operating Officer of that
Division.

KENNETH L. SCOTT, CHIEF OPERATING OFFICER: Mr. Scott has been Chief Operating
Officer of the Company since January 1997. From February 1996 to January 1997,
he served as Chief Operating Officer of the Company's IMPACT division.
Previously, Mr. Scott was President and Chief Executive Officer of American
Health Care Management Services, Inc., an oncology healthcare management
consulting company, from June 1993 to February 1996.

CARLTON N. SEDBERRY, EXECUTIVE VICE PRESIDENT OF DEVELOPMENT: Mr. Sedberry has
been Executive Vice President of Development for the Company since May 1997.
Previously, he served as Vice President of Development of the Company's IMPACT
Division from January 1996 to May 1997, as the Western Region Director of
Operations from June 1993 to January 1996 and as Director of Pharmacy from
September 1989 to June 1993. Prior to joining the Company Mr. Sedberry served as
Director of Southeast Region for Pharmacy Operations of National Medical
Enterprises, Inc.



                                       10

<PAGE>   12

EMPLOYMENT CONTRACTS; CHANGE OF CONTROL ARRANGEMENTS

         Each of the executive officers named in the tables below has executed,
effective as of January 1, 1998, an employment contract providing for the
continued employment of each of the named executives. Each contract is for a
term of three years and is automatically renewed for a one year period unless
notice of termination is given on the anniversary date preceding its expiration.
The employment contracts provide for the following base salaries, plus in each
case a bonus of up to 100% of the executive's base salary: Dr. West - $234,000;
Mr. Clark - $234,000; Mr. Scott - $185,000; Ms. Clements - $150,000 and Mr.
Sedberry - $115,000. Annual bonuses are determined in accordance with policies,
and are based on performance targets, established by the Compensation Committee.
In addition, each executive is entitled to all other employee benefits for which
any salaried employee of the Company is eligible.

         Each employment contract provides for termination of salary as of the
date of termination due to death or disability, as well as upon a termination
for cause by the Company or voluntary termination by the executive. Cause is
defined as conviction of a felony, perpetration of fraud, embezzlement or other
act of dishonesty or the executive's breach of trust or fiduciary duties in a
manner that materially adversely affects the Company or its shareholders.

         If an executive's employment is terminated by the Company without cause
or the executive suffers a "constructive termination" of employment (defined as
(a) a declined reassignment to a job that is not the equivalent of the
executive's then-current position either in terms of scope of duties or location
of employment, or (b) conduct by the Company or the board of directors that is a
continuous and material interference with the executive's ability to perform the
duties of his position), and there has not been a change in control of the
Company, then the executive is entitled a lump sum severance payment equal to
100% of his or her then-current base salary plus 100% of the average annual
incentive bonus paid to the executive during the two years immediately preceding
such termination.

         In the event the executive's employment is terminated without cause or
the executive suffers a constructive termination within one year following a
change in control, the executive is entitled to a lump sum severance payment
equal to (1) 200% (299% in the case of Dr. West and Mr. Clark) of the sum of the
executive's base salary as in effect at the time of termination plus the
executive's average annual incentive bonus for the two years immediately
preceding such termination, plus (2) the amount of any excise tax incurred by
the executive pursuant to the "excess parachute payment" rules under the
Internal Revenue Code of 1996, as amended; provided that the foregoing excise
tax gross-up is limited for all executives of the Company to an aggregate amount
of $5 million.

         While the executive is employed by the Company and for a period of one
year following termination of employment for any reason (except upon the
Company's failure to renew), the executive has agreed not to compete with the
Company.



                                       11
<PAGE>   13


COMPENSATION TABLES

         The following table sets forth the compensation for services rendered
for each of the Company's last three fiscal years, of the Chief Executive
Officer and the Company's other four most highly compensated executive officers
whose total annual salary and bonus exceeded $100,000:

                           SUMMARY COMPENSATION TABLE



<TABLE>
<CAPTION>
                                          ANNUAL                 LONG TERM                            
                                       COMPENSATION         COMPENSATION AWARDS                       
- --------------------------------------------------------------------------------------------------------
   NAME AND PRINCIPAL                                        OPTIONS/           LTIP         ALL OTHER
        POSITION             YEAR      SALARY     BONUS        SARs            PAYOUTS      COMPENSATION
- --------------------------------------------------------------------------------------------------------
<S>                          <C>     <C>        <C>          <C>               <C>         <C>      
                             1998   $234,000   $ 70,200             0            0         $1,250 (1)
Joseph T. Clark,             1997    212,954    110,837       344,749            0          1,250 (1)
President and CEO            1996    205,231     50,800        25,000            0          1,358 (1)

Mary E. Clements             1998   $150,000   $ 45,000             0            0         $1,250 (1)
Chief Financial Officer      1997    127,539     62,421       130,000            0          1,154 (1)
                             1996     38,462     15,000        75,000            0                 0


                             1998   $185,000   $ 55,500             0            0         $1,250 (1)
Kenneth L. Scott             1997    175,000     90,030       157,331            0          1,250 (1)
Chief Operating Officer      1996    120,192     25,850       120,000            0          1,053 (1)


Carlton N. Sedberry          1998   $115,000   $ 69,000             0            0         $1,250 (1)
Executive Vice President     1997    104,375     69,000       120,555            0          1,250 (1)
of Development               1996     94,584     49,700         4,000            0          1,250 (1)

                             1998   $234,000   $ 70,200             0            0         $       0
                             1997    234,000    110,837       209,149            0                 0
William H. West, M.D.        1996    230,885     49,300        25,000            0            108 (1)
Chairman
</TABLE>


(1)      Reflects Company contributions paid or accrued to the named executive's
         account in the Company's 401(k) Profit Sharing Plan and Trust and
         premiums paid for term life insurance.


                                       12
<PAGE>   14


Option Grants as of December 31, 1998. No option grants were made to any of the
Company's executive officers during the 1998 fiscal year.


Aggregated Option Exercises through December 31, 1998. The following table
provides information with respect to the value of each of their unexercised
options at December 31, 1998. No executive officer exercised any options during
the year ended December 31, 1998.


                 AGGREGATE OPTION EXERCISES IN LAST FISCAL YEAR
                        AND FISCAL YEAR END OPTION VALUES

<TABLE>
<CAPTION>
                                            Number of Shares Underlying        Value of Unexercised
                                                Unexercised Options             In-the-Money Options
                                                at Fiscal Year End            at December 31, 1998(1)
                                       ---------------------------------------------------------------------
                Name                   Exercisable       Unexercisable        Exercisable      Unexercisable
                ----                   -----------       -------------        -----------      -------------
           <S>                         <C>               <C>                  <C>              <C>
           Joseph T. Clark                383,549              0               $ 91,194          $0      
                                                                                                           
           Mary E. Clements               130,000              0               $      0          $0      

           Kenneth L. Scott               157,331              0               $      0          $0      
                                                                                                           
           Carlton N. Sedberry            126,555              0               $ 11,878          $0      
                                                                                                           
           William H. West                259,149              0               $ 50,060          $0      
</TABLE>

(1)   Based upon the closing price of $4.06 per share of the Common Stock on
      the The Nasdaq Stock Market on December 31, 1998.




                                       13
<PAGE>   15


                      REPORT OF THE COMPENSATION COMMITTEE

         The Compensation Committee of the Board of Directors (the "Committee")
is composed entirely of Independent Directors. The Committee meets periodically
to review and recommend for Board approval the Company's compensation program
for senior executives and other key employees and independently administers the
stock option and other incentive plans of the Company.

         The guiding principle of the Committee is to establish a compensation
program which aligns executive compensation with the Company's objectives,
business strategies and financial and operational performance. In connection
with this principle, the Committee seeks to:

         (1) Attract and retain qualified executives in the highly competitive
health care industry who will play a significant role in the achievement of the
Company's goals.

         (2) Create a performance oriented environment that rewards performance
with respect to the financial and operational goals of the Company and which
takes into account industry-wide trends and performance levels.

         (3) Reward executives for the strategic management and the long-term
enhancement of shareholder value.

         Compensation for the key executives consists of three elements: base
salary and benefits, a performance based annual cash bonus and stock-based
compensation.

         While the Committee seeks to weigh each element separately, it is their
collective value that is considered in ensuring that the executive officers are
appropriately compensated in a manner that advances both the short-term and
long-term interests of the shareholders.

         The base salary for each executive officer is set on the basis of the
salary levels in effect for comparable positions in the industry, adjusted for
the executive's experience and performance level and internal comparability
considerations. The Company monitors industry salary levels with the assistance
of a compensation consultant. For 1998, the committee believes the executive
officers' base salaries were competitive with salaries for individuals in
comparable positions based on an industry survey commissioned by the Committee.

INCENTIVE COMPENSATION

         An executive officer's performance-based annual cash bonus is based
upon pre-established financial goals as well as the achievement of strategic
objectives and milestones. The primary financial goal set by the Committee has
been achievement of target levels of earnings before interest and taxes (EBIT).
An aggregate incentive pool is determined by taking a percentage of EBIT and
allocating it among participants. In establishing a minimum level of EBIT before
any bonuses are earned the Committee considers prior fiscal year performance and
the amount of increase budgeted for the coming year. The percentage of EBIT
credited to the bonus pool may be increased if actual EBIT exceeds budgeted
EBIT. Based upon the CEO's recommendation as to the participant's contribution
to the overall success in achieving the EBIT results, officers may earn from 10%
to 100% of base salary. Achievement of strategic objectives and milestones may
also be a portion of an individual's performance-based annual cash bonus,
including the number of new IMPACT Center openings, development of
infrastructure necessary to sustain future growth, obtaining financing on
favorable terms, or more recently with diversification into the physician
practice management business and the number of physicians under management. For
1998, the Committee placed significant emphasis on the fact that large reserves
with respect to three unprofitable physician practice management relationships
were recorded in the fourth quarter resulting in an annual loss, reducing
incentive compensation significantly below 1997 levels.


                                       14

<PAGE>   16


STOCK INCENTIVES

         Pursuant to the Company's various stock option and incentive plans, the
Committee periodically awards stock options to executive officers, key
employees, and consultants to the Company and its subsidiaries. Pursuant to the
1996 Stock Incentive Plan the Committee has the ability to award shares of
restricted stock and stock appreciation rights (whether separate or in tandem
with stock options) in addition to stock options. Such stock based compensation
provides for an incentive for each participant to become a meaningful
shareholder of the Company and provides a mechanism for aligning those
participants' interests with those of the shareholders. The Committee believes
that such stock option grants are the foundation in the overall compensation
packages of the Company's senior management because such grants recognize both
productivity and profitability, while at the same time giving recipients a
vested long term interest in the success of the Company through stock ownership.

COMPENSATION OF CHIEF EXECUTIVE OFFICER

         Mr. Clark's base salary is set using the same criteria as all other
executive officers. His 1998 cash bonus was substantially less than his 1997
cash bonus primarily because of the Company's large fourth quarter and annual
losses resulting from substantial additional reserves being established with
respect to three unprofitable physician practice management relationships. Mr.
Clark's cash bonus was 50% of the maximum bonus provided in his employment
agreement.

COMPENSATION COMMITTEE

P. Anthony Jacobs (Chairman)
Frank M. Bumstead
Lawrence Kugelman
James R. Seward


                                       15

<PAGE>   17


                                PERFORMANCE GRAPH

         The graph below sets forth the cumulative total return to Response
Oncology, Inc.'s shareholders during the five year period ended December 31,
1998, as well as an overall stock market index (Nasdaq U.S. Index) and a peer
group index (Nasdaq Health Services Index). The Company has changed its peer
group index from the S&P Health Care Services Index to the Nasdaq Health
Services Index. The Company has made this change because it believes the
companies comprising the Nasdaq Health Services Index are more comparable in
terms of size and market capitalization than those comprising the S&P Health
Care Services Index. The stock performance graph assumes $100 was invested on
December 31, 1993:



















<TABLE>
<CAPTION>
                                12/31/93        12/31/94       12/31/95        12/31/96        12/31/97      12/31/98
                                --------        --------       --------        --------        --------      --------
<S>                           <C>            <C>            <C>             <C>             <C>            <C>   
Response Oncology             $   100.00     $   103.85     $    153.85     $    116.92     $   103.14     $    49.97
Nasdaq U.S. Index             $   100.00     $    97.75     $    138.26     $    170.02     $   208.58     $   293.21
Nasdaq Health Services
Index                         $   100.00     $   107.29     $    136.11     $    135.89     $   138.49     $   118.76
S&P Health Care
Services Index                $   100.00     $    64.29     $    88.394     $    92.407     $   116.12     $   209.21
</TABLE>



                                       16
<PAGE>   18


                      COMPENSATION COMMITTEE INTERLOCKS AND
                 INSIDER PARTICIPATION IN COMPENSATION DECISIONS


         There were no compensation interlocks in 1998, and no insider
participated in decisions relating to his compensation in 1998.

                        COMPLIANCE WITH SECTION 16 UNDER
                       THE SECURITIES EXCHANGE ACT OF 1934


         Section 16(a) of the Securities Exchange Act of 1934 requires the
Company's directors, executive officers and persons who own more than 10% of the
registered class of the Company's equity securities to file reports of ownership
with the Securities and Exchange Commission. Such directors, executive officers
and shareholders are required pursuant to Securities and Exchange Commission
regulations to furnish the Company with copies of all reports filed pursuant to
Section 16(a) of the Securities Exchange Act of 1934.

         Based solely on a review of the Forms 3 and 4, and amendments thereto,
furnished to the Company during the fiscal year ended December 31, 1998 and Form
5, and amendments thereto, furnished to the Company with respect to such fiscal
year, and certain representations furnished to the Company, the Company believes
that during the fiscal year ended December 31, 1998 all reports under Section
16(a) of the Securities Exchange Act of 1934 required to be filed by directors,
executive officers and 10% shareholders of the Company were timely filed.


THE BOARD OF DIRECTORS RECOMMENDS A VOTE "FOR" EACH OF THE NOMINEES FOR CLASS
III DIRECTORS.





                                       17
<PAGE>   19


                                   PROPOSAL 2.
                      RATIFICATION OF SELECTION OF KPMG LLP
                AS THE 1999 INDEPENDENT ACCOUNTANTS AND AUDITORS

         The Board of Directors has selected KPMG LLP as the Company's
independent auditors for 1999. The selection is subject to approval by the
shareholders not later than the date of the Annual Meeting. KPMG LLP served as
independent auditors of the Company for the years ended December 31, 1993
through 1998. Representatives of the firm will be present at the Annual Meeting,
have an opportunity to make a statement if they so desire and are expected to be
available to respond to appropriate questions.

         The affirmative vote of the holders of a majority of the outstanding
shares of Common Stock entitled to vote at the Meeting is required to ratify the
selection of KPMG LLP as the Company's independent auditors for 1999.

   THE BOARD OF DIRECTORS RECOMMENDS A VOTE "FOR" ADOPTION OF PROPOSAL NO. 2.






                                       18
<PAGE>   20


                         SHAREHOLDER PROPOSALS FOR 2000

         Pursuant to the Securities Exchange Act of 1934, shareholder proposals
intended to be presented at the 2000 annual meeting of shareholders of the
Company must be received by the Company at its executive offices on or before
January 10, 2000.


                                  OTHER MATTERS

         The Board of Directors knows of no other business to be brought before
the meeting. If any other matters properly come before the meeting, the proxies
will be voted on such matters in accordance with the judgment of the persons
named as proxies therein, or their substitutes, present and acting at the
meeting.


                           INCORPORATION BY REFERENCE

         The consolidated financial statements of the Company, included in the
Company's 1998 Annual Report which accompanies this Proxy Statement, are hereby
incorporated by reference into this Proxy Statement as if stated verbatim
herein.


                       BY ORDER OF THE BOARD OF DIRECTORS




                                MARY E. CLEMENTS
                                    Secretary
April 25, 1999













                                       19


<PAGE>   21
 
                            RESPONSE ONCOLOGY, INC.
                    PROXY FOR ANNUAL MEETING OF SHAREHOLDERS
                                 JUNE 10, 1999
 
    The Undersigned hereby appoints Mary E. Clements as true and lawful attorney
or attorney-in-fact of the undersigned, with full power of substitution, to vote
a proxy for the undersigned at the Annual Meeting of the Shareholders for
Response Oncology, Inc. (the "Company") to be held at the Company's corporate
offices located at 1805 Moriah Woods Boulevard, Memphis, Tennessee at 11:00
a.m., local time, on June 10, 1999, and all adjournments thereof, the number of
shares of which the undersigned would be entitled to vote if then personally
present for the following purposes:
 
1. To elect three Class III directors to serve one year terms ending in 2000, or
   until their successors have been duly elected and qualified.
 
   [ ] FOR all nominees listed below    [ ] AGAINST all nominees listed below   
   [ ] ABSTAIN
     (except as marked to the contrary below)
 
- --------------------------------------------------------------------------------
 
INSTRUCTION:  To withhold authority to vote for any individual nominee, strike a
              line through the nominee's name in the list below:
 
                           Class III Directors:  Joseph T. Clark    W. Thomas
                                                 Grant, II     James R. Seward
 
2. To ratify the selection of KPMG LLP as the Company's independent auditors for
   1999.
 
     [ ]FOR                [ ] AGAINST                [ ] ABSTAIN
 
                          (Continued on reverse side)
 
                          (Continued from other side)
 
    This proxy, which is solicited on behalf of the Board of Directors of
Response Oncology, Inc. will be voted in the manner described herein. If no
direction is made, this proxy will be voted FOR all the proposals listed.
 
                                                 Date:                    , 1999
 
                                                   -----------------------------
 
                                                 -------------------------------
                                                 Signature
 
                                                 -------------------------------
                                                 Signature if Held Jointly
 
                                                 NOTE: Please date and sign
                                                 exactly as name appears hereon.
                                                 When signing as attorney,
                                                 executor, administrator,
                                                 trustee or guardian, please
                                                 give full title as such. If a
                                                 corporation, please sign full
                                                 name by authorized officer.
 
 
</SEC-DOCUMENT>
-----END PRIVACY-ENHANCED MESSAGE-----
Additional Files
FileSequenceDescriptionTypeSize
0000950144-99-005191.txt   Complete submission text file   56672

© 2019 SEC.report
SEC CFR Title 17 of the Code of Federal Regulations.